Plastic Surgery Doctors in Kansas City, KS Accepting Medicare

8 Plastic Surgery doctors found. Showing 1 - 8

Dr. Eric Christian Lai, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, Mail Code 3015, Kansas City, KS 66160 Phone: 913-588-2000    Fax: 913-588-2061

Dhaval Bhavsar, M.D. Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, Ms 3015, Kansas City, KS 66103 Phone: 913-588-2000

Dr. Michelle De Souza, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, Mail Stop 3015, Kansas City, KS 66160 Phone: 913-588-2000

Matthew Allan Miller, Plastic Surgery Medicare: Medicare Enrolled Practice Location: 3901 Rainbow Blvd, Kansas City, KS 66160 Phone: 913-588-5000

Dr. Levi James Young, M.D. Plastic Surgery Medicare: Not Enrolled in Medicare Practice Location: 3901 Rainbow Blvd, Kansas City, KS 66160 Phone: 913-588-2000

Dr. Meredith S. Collins, M.D. Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 4000 Cambridge St # Ms 3015, Kansas City, KS 66160 Phone: 913-588-2000    Fax: 913-588-2061

Raven Henderson, M.D. Plastic Surgery Medicare: May Accept Medicare Assignments Practice Location: 8040 Parallel Pkwy Ste 112a, Kansas City, KS 66112 Phone: 913-608-4586    Fax: 270-216-6827

Dr. Richard A Korentager, M.D. Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, Department Of Surgery, Kansas City, KS 66160 Phone: 913-588-2067

News Archive

Polynoma initiates POL 103A Phase III trial in melanoma

Polynoma LLC, a U.S. oncology-focused biopharmaceutical company within Hong Kong-based CK Life Sciences Int'l., today announced the start of a Phase III clinical trial program for POL 103A, the Company's novel melanoma vaccine. Polynoma's global, multi-center, double-blind, placebo-controlled Melanoma Antigen Vaccine Immunotherapy Study (MAVIS) is designed to enroll a total of 1059 patients with resected Stage IIb, IIc or III melanoma.

Mount Sinai's Arnhold Institute for Global Health and NYC Health + Hospitals launch CURE-19

The Arnhold Institute for Global Health at the Icahn School of Medicine at Mount Sinai and NYC Health + Hospitals have launched the COVID-19 Unit for Research at Elmhurst (CURE-19).

Abbott's Humira gains first-line biologic use for psoriasis treatment: Report

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that while Amgen/Stiefel/Pfizer's Enbrel is the most popular biologic across all lines of therapy for psoriasis treatment in newly diagnosed patients, Abbott's Humira is gaining increasing use as a first-line biologic at Enbrel's expense.

Study shows spinal cord stimulation can be safe, effective treatment option for chronic pain sufferers

Chronic pain affects up to 20% of people in developed countries, and represents not only a profound impact on individuals and their families but also a sizeable burden on employers, health care systems, and society in general.

FDA completes IIWA to curb illegal actions involving medical products

The U.S. Food and Drug Administration today completed a coordinated, weeklong, international effort, called the International Internet Week of Action (IIWA), intended to curb illegal actions involving medical products.

Read more Medical News

› Verified 9 days ago